About Osivax
Osivax is a company based in Lyon (France) founded in 2017.. Osivax has raised $42.21 million across 9 funding rounds from investors including Gates Foundation, Bpifrance and Meiji Group. Osivax offers products and services including oligoDOM TM, OVX836, and OVX033. Osivax operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, Vir Biotechnology, Biological E and Freeline, among others.
- Headquarter Lyon, France
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$42.21 M (USD)
in 9 rounds
-
Latest Funding Round
$10.45 M (USD), Series B
Mar 04, 2025
-
Investors
Gates Foundation
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Osivax
Osivax offers a comprehensive portfolio of products and services, including oligoDOM TM, OVX836, and OVX033. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform technology for developing vaccines against mutating pathogens.
Vaccine candidate targeting influenza through T-cell responses.
Vaccine candidate for coronavirus infections using nanoparticle approach.
Funding Insights of Osivax
Osivax has successfully raised a total of $42.21M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $10.45 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $10.5M
-
First Round
First Round
(15 Jun 2017)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2025 | Amount | Series B - Osivax | Valuation |
investors |
|
| Dec, 2023 | Amount | Grant - Osivax | Valuation |
investors |
|
| Mar, 2023 | Amount | Grant - Osivax | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Osivax
Osivax has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Bpifrance and Meiji Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Noshaq is recognized as a Liège-based investment fund providing financing solutions.
|
Founded Year | Domain | Location | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Dairy products are produced and marketed by Meiji Group.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Osivax
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Osivax
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Osivax Comparisons
Competitors of Osivax
Osivax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, Vir Biotechnology, Biological E and Freeline, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Osivax
Frequently Asked Questions about Osivax
When was Osivax founded?
Osivax was founded in 2017.
Where is Osivax located?
Osivax is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Is Osivax a funded company?
Osivax is a funded company, having raised a total of $42.21M across 9 funding rounds to date. The company's 1st funding round was a Grant of $1M, raised on Jun 15, 2017.
What does Osivax do?
Osivax was founded in 2017 in Lyon, France, within the biotechnology sector focused on vaccine development. Proprietary oligoDOM nanoparticle technology is utilized to elicit T-cell responses against constantly mutating pathogens. Operations center on advancing candidates like OVX836, which targets influenza and coronavirus. Research and development activities are conducted to address challenges in pathogen evolution and immune response enhancement.
Who are the top competitors of Osivax?
Osivax's top competitors include Vaxcyte, Serum Institute of India and Biological E.
What products or services does Osivax offer?
Osivax offers oligoDOM TM, OVX836, and OVX033.
Who are Osivax's investors?
Osivax has 8 investors. Key investors include Gates Foundation, Bpifrance, Meiji Group, European Union, and Anaxago.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.